Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
CCRN vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
CCRN vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $326M | $1721.78T |
| Revenue (TTM) | $1.05B | $0.00 |
| Net Income (TTM) | $-95M | $-168M |
| Gross Margin | 18.7% | — |
| Operating Margin | -0.3% | — |
| Forward P/E | 103.4x | — |
| Total Debt | $2M | $22M |
| Cash & Equiv. | $109M | $194M |
CCRN vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cross Country Healt… (CCRN) | 100 | 166.6 | +66.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCRN vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CCRN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.78
- Rev growth -21.6%, EPS growth -5.7%, 3Y rev CAGR -27.8%
- -28.1% 10Y total return vs DBVT's -86.8%
DBVT is the clearest fit if your priority is quality and momentum.
- 0.3% margin vs CCRN's -9.0%
- +114.1% vs CCRN's -26.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -21.6% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs CCRN's -9.0% | |
| Stability / Safety | Beta 0.78 vs DBVT's 1.26, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +114.1% vs CCRN's -26.6% | |
| Efficiency (ROA) | -17.9% ROA vs DBVT's -89.0% |
CCRN vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CCRN vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CCRN and DBVT operate at a comparable scale, with $1.1B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.1B | $0 |
| EBITDAEarnings before interest/tax | $13M | -$112M |
| Net IncomeAfter-tax profit | -$95M | -$168M |
| Free Cash FlowCash after capex | $42M | -$151M |
| Gross MarginGross profit ÷ Revenue | +18.7% | — |
| Operating MarginEBIT ÷ Revenue | -0.3% | — |
| Net MarginNet income ÷ Revenue | -9.0% | — |
| FCF MarginFCF ÷ Revenue | +4.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -20.3% | +91.5% |
Valuation Metrics
Evenly matched — CCRN and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $326M | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $220M | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | -3.45x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 103.37x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 16.49x | — |
| Price / SalesMarket cap ÷ Revenue | 0.31x | — |
| Price / BookPrice ÷ Book value/share | 1.01x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 6.76x | — |
Profitability & Efficiency
CCRN leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
CCRN delivers a -24.3% return on equity — every $100 of shareholder capital generates $-24 in annual profit, vs $-130 for DBVT. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), CCRN scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -24.3% | -130.2% |
| ROA (TTM)Return on assets | -17.9% | -89.0% |
| ROICReturn on invested capital | -0.9% | — |
| ROCEReturn on capital employed | -0.8% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x |
| Net DebtTotal debt minus cash | -$106M | -$172M |
| Cash & Equiv.Liquid assets | $109M | $194M |
| Total DebtShort + long-term debt | $2M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -1.56x | -189.82x |
Total Returns (Dividends Reinvested)
Evenly matched — CCRN and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CCRN five years ago would be worth $6,276 today (with dividends reinvested), compared to $3,344 for DBVT. Over the past 12 months, DBVT leads with a +114.1% total return vs CCRN's -26.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs CCRN's -24.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +25.4% | +5.5% |
| 1-Year ReturnPast 12 months | -26.6% | +114.1% |
| 3-Year ReturnCumulative with dividends | -57.0% | +20.4% |
| 5-Year ReturnCumulative with dividends | -37.2% | -66.6% |
| 10-Year ReturnCumulative with dividends | -28.1% | -86.8% |
| CAGR (3Y)Annualised 3-year return | -24.5% | +6.4% |
Risk & Volatility
Evenly matched — CCRN and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.8% from its 52-week high vs CCRN's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 1.26x |
| 52-Week HighHighest price in past year | $14.99 | $26.18 |
| 52-Week LowLowest price in past year | $7.43 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +67.4% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 67.4 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 451K | 253K |
Analyst Outlook
CCRN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates CCRN as "Hold" and DBVT as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 4.9% for CCRN (target: $11).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $10.61 | $46.33 |
| # AnalystsCovering analysts | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CCRN leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). DBVT leads in 1 (Income & Cash Flow). 3 tied.
CCRN vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CCRN or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCRN or DBVT?
Over the past 5 years, Cross Country Healthcare, Inc.
(CCRN) delivered a total return of -37. 2%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: CCRN returned -28. 1% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCRN or DBVT?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 62% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — CCRN or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CCRN or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — CCRN leads at 18. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CCRN or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 130.
5% to $46. 33.
07Which pays a better dividend — CCRN or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CCRN or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Cross Country Healthcare, Inc.
(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (CCRN: -28. 1%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CCRN and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.